Atlantic International Corp.
NASDAQ:ATLNMedical - Diagnostics & Research
-$0.10 today
- Market cap
- $73.17M
- Beta
- 0.71
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.08
Volume 18.56M
Average 0.44M
ATLN Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Atlantic International Corp.NASDAQ: ATLN
Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025
Cost of revenue declines year over year
Q4 FY2025 cost of revenue of $109.07M fell 6.1% year over year, behind the -1.4% change in trailing-twelve-month cost of revenue. Sequentially, it rose 11.6% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.
Context
- Cost of revenue amounted to 89.4% of revenue in FY2025, up 0.1 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -6.1% toward the trailing-twelve-month pace of -1.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 389.89M USD
- Year-over-year change
- -1.4%
- 4-year CAGR
- +1.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 389.89M | -1.4% |
| FY2024 | 2024-12-31 | 395.43M | +11.5% |
| FY2023 | 2023-12-31 | 354.5M | -8.5% |
| FY2022 | 2022-12-31 | 387.34M | +4.5% |
| FY2021 | 2021-12-31 | 370.62M | — |
Cost of Revenue vs competitors
How ATLN compares with its peers on the latest reported figures
- ATLN's LTM Dec 2025 cost of revenue of $389.89M is the highest of the 8 companies compared; the peer median is $1.72M.
- Its year-over-year change of -1.4% is the 5th highest of 6, against a peer median of +110.1%.
- Cost of revenue amounts to 89.4% of revenue for ATLN, versus a peer median of 52.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ATLNAtlantic International Corp. | LTM Dec 2025 | $389.89M | -1.4% | +0.2% | 89.4% |
| LTM Mar 2026 | $78.91M | +141.8% | +70.6% | 52.0% | |
| LTM Mar 2026 | $47.41M | +110.1% | +65.9% | 41.7% | |
| LTM Mar 2026 | $2.34M | — | — | — | |
| LTM Mar 2026 | $1.72M | +351.6% | — | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $1.57M | -13.9% | +58.2% | 80.5% |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.33M | +13.5% | -8.4% | 71.7% |
| LTM Mar 2026 | $95K | — | — | 5.3% | |
| Peer median (excluding ATLN) | $1.72M | +110.1% | +62.1% | 52.0% | |
Competitors are the stored peer set for ATLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 425.03M | 441.54M | 401.37M | 442.61M | 435.88M |
| Cost of Revenue | 370.62M | 387.34M | 354.5M | 395.43M | 389.89M |
| Gross Profit | 54.41M | 54.21M | 46.88M | 47.18M | 45.99M |
| Gross Margin | 12.8% | 12.3% | 11.7% | 10.7% | 10.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 42.18M | 42.27M | 45.44M | 64.02M | 91.29M |
| Operating Expenses | 90.14M | 48.23M | 50.33M | 69.01M | 96.22M |
| Depreciation & Amortization | 4.11M | 5.07M | 5.04M | 4.99M | 6.59M |
| EBITDA | 12.18M | 11.94M | 1.44M | (113.1M) | (43.64M) |
| EBITDA Margin | 2.9% | 2.7% | 0.4% | -25.6% | -10.0% |
| Operating Income | (35.73M) | 5.98M | (3.45M) | (21.83M) | (50.23M) |
| Operating Margin | -8.4% | 1.4% | -0.9% | -4.9% | -11.5% |
| Interest Income | 36.46K | 44.88K | 0 | 0 | 0 |
| Interest Expense | 208.29K | 90.75K | 17.54M | 12M | 9.16M |
| Other Income / Expenses | (3.73M) | (8.39M) | (17.73M) | (108.27M) | (9.16M) |
| Income Before Tax | (39.46M) | (2.41M) | (21.18M) | (130.1M) | (59.4M) |
| Pre-Tax Margin | -9.3% | -0.5% | -5.3% | -29.4% | -13.6% |
| Income Tax Expense | 1.33M | 808.43K | (5.93M) | 5.38M | 33.99K |
| Net Income | (40.8M) | (3.22M) | (15.25M) | (135.48M) | (59.43M) |
| Net Margin | -9.6% | -0.7% | -3.8% | -30.6% | -13.6% |
| EPS (Basic) | (0.17) | (0.19) | (0.60) | (3.68) | (1.08) |
| EPS (Diluted) | (0.17) | (0.17) | (0.60) | (3.68) | (1.08) |
| Weighted Avg Shares | 21.69M | 21.69M | 25.42M | 36.78M | 54.85M |
| Weighted Avg Shares (Diluted) | 21.69M | 24.14M | 25.42M | 36.78M | 54.85M |
Atlantic International Corp.
NASDAQ:ATLN
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.